This US-based company is a leader in cell-based phenotypic testing technologies and assays. It has developed a technology to identify a wide range of microbial species through simple phenotypic testing.
The company wanted to quickly assess the potential of the European market for its flagship product, which can rapidly identify over 2,500 species of aerobic and anaerobic bacteria, yeasts and fungi. The company wanted to benefit from an upcoming ECCMID conference to get meaningful feedback from key opinion leaders in the field of bacterial characterisation.
Novoptim rapidly assembled a project team to launch a campaign that would result in meetings during the conference. Despite the short notice, we were able to build a comprehensive landscape in bacterial detection in Europe with key players and potential partners.
Novoptim organized meetings with 11 KOLs from 10 different hospitals and research centres, collected their feedback on the technology (pros and cons), identified potential reference sites, and ranked KOL interest against reputation and size. As a next step, the company is now contacting the short list of KOLs to initiate collaborations. As a next step, the company is now contacting the short list of KOLs to engage the collaboration.